MMP-2 Human, HEK
目录号 : GP25563Matrix Metalloproteinase-2 Human Recombinant, HEK
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MMP-2 Human Recombinant produced in HEK293 cells is a proform of the Human MMP-2 (Ala30-Cys660) and fused with a ployhistide tag at the C-terminus, having an Mw of 71kDa.
MMP-2 is purified by proprietary chromatographic techniques.
| Purity | Purity Greater than 95% as determined by SDS-PAGE. | Source | HEK293 cells. |
| Phycical Appearance | The MMP-2 is supplied as a sterile Filtered colorless solution. | Shipping Condition | Shipped with Ice Packs |
| Synonyms | 72 kDa type IV collagenase, 72 kDa gelatinase, Gelatinase A, Matrix metalloproteinase-2, MMP-2, TBE-1, MMP2, CLG4A, CLG4, MONA, MMP-II. | ||
| Stability | Store MMP-2 at 4°C if entire vial will be used within 2-4 weeks. Store frozen at -20°C for longer periods of time. Avoid multiple freeze-thaw cycles. | ||
| Biological Activity | The activity was measured by its ability to cleave fluorogenic peptide substrate, Mca-PLGL-Dpa-AR-NH2 (RND,Catalog # ES001)., The specific activity is > 1,000 pmoles/min/µg. Recombinant Human MMP-2 protein pro form needs to be activated with p-aminophenylmercuric acetate (APMA). Activation Protocol: 1. Dilute MMP2 to 100µg/ml in the Assay Buffer: 50mM Tris, 10mM CaCl2, 150mM NaCl, 0.05% (w/v) and Brij 35, pH 7.5. 2. Activate MMP2 by adding APMA to a final concentration of 1mM. (Sigma, Catalog # A9563) and 100mM stock in DMSO. 3. Incubate at 37°C for 1 hour. | ||
| Formulation | The MMP-2 is supplied as a 0.2µm filtered solution in 20mM Tris-HCl, 150mM NaCl and 0.05% Brij 35, pH 7.4. | ||
Matrix metalloproteinase-2 (MMP-2) is a type IV collagenase, which is involved in endometrial menstrual breakdown, regulation of vascularization and the inflammatory response. MMP-2 contains a number of distinct domains: a prodomain that is cleaved upon activation; a catalytic domain containing the zinc binding site; a fibronectin like domain believed to have a role in substrate targeting; and a carboxyl terminal (hemopexin like) domain containing 2 N-linked glycosylation. The MMP-2 can degrade an extensive array of substrates including type IV, V, VII and X collagens as well as gelatin type I. In addition, MMP-2 interacts with THBS2, TIMP2, Thrombospondin 1, CCL7 and TIMP4. MMP-2 autocatalytic cleavage in the C-terminal generates the anti-angiogenic peptide, PEX. This process seems to be made possible by binding integrinv/beta3. Defects in the MMP-2 are the cause of Torg-Winchester syndrome (TWS), aka multicentric osteolysis nodulosis and arthropathy (MONA).
The activity was measured by its ability to cleave fluorogenic peptide substrate, Mca-PLGL-Dpa-AR-NH2 (RND,Catalog # ES001)., The specific activity is > 1,000 pmoles/min/µg. Recombinant Human MMP-2 protein pro form needs to be activated with p-aminophenylmercuric acetate (APMA). Activation Protocol: 1. Dilute MMP2 to 100µg/ml in the Assay Buffer: 50mM Tris, 10mM CaCl2, 150mM NaCl, 0.05% (w/v) and Brij 35, pH 7.5. 2. Activate MMP2 by adding APMA to a final concentration of 1mM. (Sigma, Catalog # A9563) and 100mM stock in DMSO. 3. Incubate at 37°C for 1 hour.
Store MMP-2 at 4°C if entire vial will be used within 2-4 weeks. Store frozen at -20°C for longer periods of time. Avoid multiple freeze-thaw cycles.